IL166431A0 - Microcapsules with modified release of active principles with low solubility for oral delivery - Google Patents

Microcapsules with modified release of active principles with low solubility for oral delivery

Info

Publication number
IL166431A0
IL166431A0 IL16643105A IL16643105A IL166431A0 IL 166431 A0 IL166431 A0 IL 166431A0 IL 16643105 A IL16643105 A IL 16643105A IL 16643105 A IL16643105 A IL 16643105A IL 166431 A0 IL166431 A0 IL 166431A0
Authority
IL
Israel
Prior art keywords
microcapsules
low solubility
modified release
oral delivery
active principles
Prior art date
Application number
IL16643105A
Other languages
English (en)
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of IL166431A0 publication Critical patent/IL166431A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
IL16643105A 2002-07-26 2005-01-20 Microcapsules with modified release of active principles with low solubility for oral delivery IL166431A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0209530A FR2842735B1 (fr) 2002-07-26 2002-07-26 Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
PCT/FR2003/002384 WO2004010984A2 (fr) 2002-07-26 2003-07-28 Microcapsules a liberation modifiee de principes actifs peu solubles pour administration per os

Publications (1)

Publication Number Publication Date
IL166431A0 true IL166431A0 (en) 2006-01-15

Family

ID=30011527

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16643105A IL166431A0 (en) 2002-07-26 2005-01-20 Microcapsules with modified release of active principles with low solubility for oral delivery

Country Status (13)

Country Link
US (2) US20060275376A1 (xx)
EP (2) EP2272506A3 (xx)
JP (1) JP2005535680A (xx)
KR (1) KR20050026518A (xx)
CN (1) CN1681483B (xx)
AU (1) AU2003269068B2 (xx)
BR (1) BR0312988A (xx)
CA (1) CA2493464C (xx)
FR (1) FR2842735B1 (xx)
IL (1) IL166431A0 (xx)
MX (1) MXPA05001076A (xx)
WO (1) WO2004010984A2 (xx)
ZA (1) ZA200500734B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
FR2869624B1 (fr) * 2004-04-28 2006-06-09 Inst Francais Du Petrole Structure et revetement auto-reparables pour milieu corrosif
FR2869764B1 (fr) * 2004-05-07 2006-07-21 Olivier Roche Complement nutrionnel liquide et procede de preparation de ce complement
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
US20090123536A1 (en) * 2005-02-21 2009-05-14 Flamel Technologies, S.A. Oral Pharmaceutical Form of Losartan
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
MX2011003749A (es) 2008-10-08 2011-09-01 Bioplus Life Sciences Pvt Ltd Sistema para suministrar medicamentos de liberacion sostenida.
FR2945945B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Procede de preparation de particules creuses et leurs applications
FR2945947B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
MX339408B (es) * 2010-03-09 2016-05-24 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas entericas resistentes al alcohol.
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2012120366A1 (en) * 2011-03-09 2012-09-13 Ideal Cures Pvt. Ltd. Novel moisture barrier immediate release film coating composition
KR101811301B1 (ko) 2011-05-24 2017-12-26 삼성전자주식회사 반도체 패키지
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
EP2922926A4 (en) * 2012-11-26 2016-07-20 Progel Pty Ltd COATING COMPOSITION
US10188609B2 (en) 2012-11-29 2019-01-29 Progel Pty Ltd Microparticles comprising a probiotic, cross-linkable reagent, a denatured protein, polyol plasticiser and trehalose
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EA036269B1 (ru) 2014-12-18 2020-10-21 Принсипиа Биофарма Инк. Лечение пузырчатки
SG11201705026UA (en) * 2014-12-24 2017-07-28 Principia Biopharma Inc Site specific dosing of a btk inhibitor
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
AU2016308953B2 (en) 2015-08-20 2020-09-10 Aseko, Inc. Diabetes management therapy advisor
BR112018014661A2 (pt) 2016-01-20 2018-12-11 Theravida Inc composição e composição para uso
CN105581996B (zh) * 2016-02-23 2018-03-27 广西梧州制药（集团）股份有限公司 一种去水卫矛醇微囊及其制备方法
MX2018016056A (es) 2016-06-29 2019-07-04 Principia Biopharma Inc Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo.
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2313915A1 (fr) * 1976-01-26 1977-01-07 Corneille Gilbert Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
LU85943A1 (fr) * 1985-06-12 1987-01-13 Galephar Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation
SE8601624D0 (sv) 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
JPH0236571B2 (ja) 1986-04-11 1990-08-17 Otsuka Pharma Co Ltd Jizokuseiseizai
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
SE509029C2 (sv) 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
IT1227899B (it) * 1988-12-23 1991-05-14 Poli Ind Chimica Spa Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
GB8913889D0 (en) 1989-06-16 1989-08-02 May & Baker Ltd New compositions of matter
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
JPH0873345A (ja) 1994-09-05 1996-03-19 Terumo Corp 医薬製剤
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
FR2732218B1 (fr) * 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
EP0953359A4 (en) 1996-12-19 2001-12-19 Daiichi Seiyaku Co PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
US5965167A (en) 1997-10-07 1999-10-12 Sanghvi; Pradeepkumar P. Dosage units
IL162023A0 (en) 1998-03-30 2005-11-20 Rtp Pharma Inc Compositions containing microparticles of water-insoluble substances and method for their preparation
JP2002525311A (ja) 1998-10-01 2002-08-13 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物
BR9916835A (pt) 1998-12-24 2001-09-25 Janssen Pharmaceutica Nv Composição de galantamina de liberação controlada
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
JP2004530676A (ja) * 2001-04-18 2004-10-07 ノストラム・ファーマスーティカルズ・インコーポレイテッド 持続放出性薬学的組成物のための新規コーティング
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
FR2837100B1 (fr) * 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
IL164221A0 (en) * 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
MXPA04009968A (es) * 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
JP6073788B2 (ja) * 2010-09-14 2017-02-01 ナノロジカ アクティエボラーグ 難水溶性医薬及び化粧品有効成分のための過飽和送達媒体

Also Published As

Publication number Publication date
US20070160678A1 (en) 2007-07-12
EP1524969A2 (fr) 2005-04-27
US8821935B2 (en) 2014-09-02
WO2004010984A2 (fr) 2004-02-05
EP2272506A3 (fr) 2013-07-10
ZA200500734B (en) 2006-03-29
CA2493464C (fr) 2012-07-03
CA2493464A1 (fr) 2004-02-05
EP2272506A2 (fr) 2011-01-12
WO2004010984A3 (fr) 2004-04-08
US20060275376A1 (en) 2006-12-07
AU2003269068A1 (en) 2004-02-16
FR2842735A1 (fr) 2004-01-30
CN1681483A (zh) 2005-10-12
FR2842735B1 (fr) 2006-01-06
MXPA05001076A (es) 2005-06-06
BR0312988A (pt) 2005-06-21
AU2003269068B2 (en) 2009-01-22
JP2005535680A (ja) 2005-11-24
CN1681483B (zh) 2011-12-28
KR20050026518A (ko) 2005-03-15

Similar Documents

Publication Publication Date Title
IL166431A0 (en) Microcapsules with modified release of active principles with low solubility for oral delivery
PL373914A1 (en) Immediate release dosage forms containing solid drug dispersions
EG25542A (en) Oral dosge forms for propiverne or pharmaceutically acceptable salts thereof having prolonged release of the active agent
EP1383376A4 (en) PHARMACEUTICAL FORMULATIONS WITH PROLONGED RELEASE
PL374347A1 (en) Solid pharmaceutical formulations comprising telmisartan
AU2003215334A1 (en) Inhalable formulations for sustained release
HK1085131A1 (en) Solid drug for oral use
EP1549296A4 (en) METFORMIN FORMULATIONS WITH DELAYED RELEASE
TWI319318B (en) Modified release pharmaceutical formulation
IL174958A0 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
EP1553925A4 (en) ORAL DOSAGE FORM WITH MODIFIED RELEASE
HK1161123A1 (zh) 含有奧曲肽微顆粒的藥物組合物
AU2003252299A8 (en) Novel physiologically active substance
AU2003232398A1 (en) Sustained release oral dosage forms of gabapentin
IL166337A0 (en) Oral administration of calctionin
EP1564220A4 (en) EXCIPIENT FOR DELAYED RELEASE MEDICINE
EP1602362A4 (en) DRUG COMPOSITION COMPRISING AN ADHESIVE ACTIVE INGREDIENT IN HIGH CONCENTRATION TO A SPHERICAL CORE
AU2003210454A8 (en) Dendritic encapsulation of active agents
IL165069A0 (en) Immediate release pharmaceutical formulation
HK1072194A1 (en) Oral dosage form for controlled drug release
PL376840A1 (pl) Kompozycja farmaceutyczna o przedłużonym uwalnianiu
AU2001248336A1 (en) Controlled release oral solid forms containing mesalazine as active agent
GB0202900D0 (en) Novel formulations of drugs
GB2392745B (en) Administration of a messaging system
AU2003254672A8 (en) Dual-spike release formulation for oral drug delivery